Table 1.
Departmental target goals and dosimetric parameters achieved for each planning type.
| Target name |
Volume (cc) Median (IQR) |
DVH Goal |
h‐VMAT Median (IQR) |
Bowtie‐VMAT Median (IQR) |
Ipsi‐VMAT Median (IQR) |
P‐Value (Welch’s t‐test) Ipsi‐VMAT vs h‐VMAT |
P‐Value (Welch’s t‐test) Ipsi‐VMAT vs Bowtie‐VMAT |
Reported range from published literature 5, 9, 14, 15, 16, 30 |
|---|---|---|---|---|---|---|---|---|
| PTVp_TB |
32.1 cc (29.7–56.4 cc) |
D95% ≥ 95% (54.15 Gy) |
56.1 Gy (55.8–56.3 Gy) |
56.2 Gy (55.9–56.4 Gy) |
56.3 Gy (56.1–56.6 Gy) |
0.14 | 0.16 | |
| D98% |
55.7 Gy (55.4–55.9 Gy) |
55.8 Gy (55.5–55.9 Gy) |
55.9 Gy (55.7–56.2 Gy) |
0.38 | 0.20 | |||
| D50% |
57.8 Gy (57.6–58.0 Gy) |
57.8 Gy (57.6–58.1 Gy) |
57.9 Gy (57.6–58.4 Gy) |
0.13 | 0.38 | |||
| D2% (max) |
59.2 Gy (59.0–59.7 Gy) |
59.6 Gy (59.2–60.1 Gy) |
59.6 Gy (59.2–60.2 Gy) |
0.03* | 0.68 | |||
| HI |
0.057 (0.053–0.064) |
0.059 (0.056–0.065) |
0.057 (0.052–0.061) |
0.89 | 0.06 | |||
| PTVp_Br |
639.4 cc (487.5–961.0 cc) |
D95% ≥ 95% (47.50 Gy) |
48.7 (48.6–49.0) |
47.5 (47.5–47.7) |
47.5 (47.5–47.5) |
<0.01* | 0.12 | 45.6–49.5 Gy |
| D98% |
48.1 Gy (47.7–48.3 Gy) |
46.4 Gy (46.3–46.6 Gy) |
46.3 Gy (46.0–46.5 Gy) |
<0.01* | 0.06 | |||
| D50% |
50.6 Gy (50.2–50.9 Gy) |
50.6 Gy (50.4–51.3 Gy) |
50.7 Gy (50.4–51.3 Gy) |
0.08 | 0.70 | |||
| D2% (max) |
58.1 Gy (57.8–58.5 Gy) |
58.1 Gy (57.9–58.5 Gy) |
58.3 Gy (57.8–58.8 Gy) |
0.25 | 0.68 | |||
| HI |
0.183 (0.175–0.196) |
0.208 (0.204–0.214) |
0.212 (0.204–0.218) |
<0.01* | 0.39 | |||
| PTVn_SCF |
91.6 cc (77.3–110.9 cc) |
D95% ≥ 95% (47.50 Gy) |
47.9 Gy (47.8–48.1 Gy) |
48.4 Gy (48.0–48.6 Gy) |
48.6 Gy (48.3–48.8 Gy) |
<0.01* | 0.18 | 42.5–48.7 Gy |
| D98% |
47.3 Gy (47.1–47.6) Gy |
47.4 Gy (46.8–47.7 Gy) |
47.7 Gy (47.1–48.0 Gy) |
0.23 | 0.29 | |||
| D50% |
49.6 Gy (49.5–49.8 Gy) |
50.5 Gy (50.3–50.9 Gy) |
50.6 Gy (50.3–51.0 Gy) |
<0.01* | 0.55 | |||
| D2% (max) |
51.1 Gy (50.9–51.2 Gy) |
52.2 Gy (51.9–52.8 Gy) |
52.2 Gy (51.8 ‐ 52.6 Gy) |
<0.01* | 0.84 | 51.5–55.0 Gy | ||
| HI |
0.063 (0.062–0.069) |
0.076 (0.071–0.084) |
0.072 (0.066–0.086) |
<0.01* | 0.22 | |||
| PTVn_Ax |
158.8 cc (123.2–204.9 cc) |
D95% ≥ 95% (47.50 Gy) |
48.0 Gy (47.9–48.2 Gy) |
48.6 Gy (48.5–48.9 Gy) |
48.7 Gy (48.5–48.8 Gy) |
<0.01* | 0.80 | 48.9–49.2 Gy |
| D98% |
47.6 Gy (47.3–47.7 Gy) |
47.8 Gy (47.6–48.1 Gy) |
48.0 Gy (47.6–48.2 Gy) |
<0.01* | 0.86 | |||
| D50% |
49.5 Gy (49.5–49.7 Gy) |
50.5 Gy (50.3–50.8 Gy) |
50.6 Gy (50.2–50.9 Gy) |
<0.01* | 0.51 | |||
| D2% (max) |
51.2 Gy (50.9–51.6 Gy) |
52.3 Gy (51.8–52.9 Gy) |
52.4 Gy (51.9–53.3 Gy) |
<0.01* | 0.97 | 55.0 Gy | ||
| HI |
0.065 (0.057–0.074) |
0.069 (0.064–0.085) |
0.072 (0.064–0.085) |
0.33 | 0.95 | |||
| PTVn_IMN |
30.1 cc (26.3–36.7 cc) |
D95% ≥ 95% (42.75 Gy) |
43.6 Gy (43.2–44.3 Gy) |
44.1 Gy (42.8–44.8 Gy) |
44.5 Gy (43.5–45.0 Gy) |
0.05* | 0.37 | 44.6–51.1 Gy |
| D98% |
42.8 Gy (42.3–43.6 Gy) |
43.0 Gy (41.5–43.8 Gy) |
43.4 Gy (42.1–44.1 Gy) |
0.37 | 0.20 | |||
| D50% |
47.4 Gy (46.8–48.0 Gy) |
48.8 Gy (48.2–49.0 Gy) |
48.8 Gy (48.5–49.2 Gy) |
<0.01* | 0.18 | |||
| D2% (max) |
50.8 Gy (50.6–50.97 Gy) |
51.9 Gy (51.5–52.3 Gy) |
51.8 Gy (51.4–52.7 Gy) |
<0.01* | 0.92 | 55.0 Gy | ||
| HI |
0.126 (0.113–0.137) |
0.126 (0.113–0.142) |
0.125 (0.109–0.154) |
0.46 | 0.72 | |||
| Conformity Index | CI (Combined PTV, 45 Gy isodose) |
0.673 (0.663–0.694) |
0.694 (0.686–0.711) |
0.712 (0.693–0.736) |
<0.01* | 0.09 | ||
|
CI (PTVp_TB, 54.15 Gy isodose) |
0.597 (0.536–0.675) |
0.586 (0.523–0.608) |
0.593 (0.531–0.640) |
0.17 | 0.74 | |||
| Monitor Units | Total MU |
839 MU (785–880 MU) |
595 MU (568–628 MU) |
652 MU (616–69 MU) |
<0.01* | <0.01* | 973–1568 MU |
PTV, planning target volume; TB, tumour bed; Br, conserved breast; SCF, supraclavicular fossa; Ax, axilla; IMN, internal mammary nodes; D, dose; V, volume; Max, maximum; cc, cubic centimetres; HI, homogeneity index; CI, conformity index; DVH, dose‐volume histogram; MU, monitor unit; IQR, interquartile range; DNE, does not exist.
*Statistically significant with P < 0.05.